ArticleScientific reports2025
A novel necroptosis related prognostic signature for skin cutaneous melanoma based on transcriptome and single cell sequencing analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ferroptosis, pyroptosis, and necroptosis in melanoma: regulatory cell death pathways and their implications for immunotherapy.Frontiers in oncology · 2026Review
- Novel immune-nutritional prognostic ratio predicts long-term survival in stage I-III colorectal cancer.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Necroptosis is a novel programmed cell death that affects the tumor heterogeneity, microenvironment, and prognosis, which is not well elucidated in skin cutaneous melanoma (SKCM). The SKCM-TCGA, GSE65904, and GSE215120 datasets were downloaded from the TCGA and GEO databases, respectively. The necroptosis-related genes were identified by weighted co-expression network analysis (WGCNA) and single-cell sequencing analysis. COX and LASSO regression was used to construct the prognostic model. Survival analysis, immune infiltration analysis, and tumor mutation analysis between the high-necroptosis score (NCPTS) and low-NCPTS groups were performed. Finally, real-time PCR experiment was carried out to verify the results. A prognostic model based on 9 necroptosis-related genes (TUFM, CD53, CLEC2D, KLRC1, STAT4, IFI35, XCL1, TAPBP, and SOD2) was constructed to predict the prognosis of SKCM patients. The patients in high-NCPTS group had a poor prognosis. The expression of immune checkpoint-related gene and drug sensitivity were higher than those in the low-NCPTS groups, indicating susceptible for immunotherapy. Real-time PCR showed that TUFM expression was significantly higher in A375 cells than control (P < 0.05). Besides, TUFM expression was also validated by TISCH and HPA database. The prognostic model might provide guidance for the prognosis and immunotherapy for SKCM patients, contributing to a better understanding of necroptosis in SKCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.